MINOCIN
LOE ApproachingNDAORALSUSPENSION
Approved
Oct 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MINOCIN by Bausch + Lomb is clinical pharmacology following a single dose of minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2. Approved for infections caused by the following gram-negative bacteria, infections caused by the following gram-positive bacteria, the treatment of the following infections due to susceptible isolates of the designated bacteria: rocky mountain spotted fever and 5 more indications. First approved in 1972.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MINOCIN (minocycline) is an oral tetracycline antibiotic suspension approved in 1972 that inhibits bacterial protein synthesis to treat a broad spectrum of gram-positive and gram-negative infections, rickettsial infections, and atypical organisms. The drug achieves serum concentrations of 1–4 mcg/mL with a half-life of 15–23 hours in healthy subjects, allowing twice-daily or once-daily dosing. MINOCIN is indicated for Rocky Mountain spotted fever, typhus, Q fever, and susceptible bacterial infections.
LOE Approaching
With LOE approaching and no current Part D spending data, the MINOCIN brand team is likely focused on defense and lifecycle extension rather than growth initiatives, suggesting a smaller, mature team.
Mechanism of Action
CLINICAL PHARMACOLOGY Following a single dose of Minocin 200 mg administered intravenously to 10 healthy male subjects, serum concentrations of minocycline ranged from 2.52 to 6.63 mcg/mL (average 4.18 mcg/mL) at the end of infusion and 0.82 to 2.64 mcg/mL (average 1.38 mcg/mL) after 12 hours. In a…
Worked on MINOCIN at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.